Live Astrazeneca Pharma India Share Price Chart

O 5487.3

H 5487.55

L 5450.05

VOL 14

Astrazeneca Pharma India Performance

Days Range

Low: ₹5,346.00
High: ₹5,492.40
Previous Close ₹5,449.20
Open ₹5,487.30
Volume 913
Day’s Range ₹5,346.00 - ₹5,492.40
52W Range ₹3,098.00 - ₹7,220.95
Market Cap ₹13,623 Cr

Astrazeneca Pharma India Fundamentals

ROCE (TTM) 35.17
P/E Ratio (TTM) 98.64
P/B Ratio 20.98
Industry P/E 45.36
Debt to Equity 0.01
ROE 26.41
EPS (TTM) 63.8
Dividend Yield 0.29
Book Value 261.99
Face Value 2

Astrazeneca Pharma India Financials

Mar 2023Jun 2023Sep 2023Dec 2023
Net Sales284.7295.46311.07305.79
Profit before tax23.2871.473.3820.4
Operating Profit17.2753.8652.3715.8
Net Profit17.2753.8652.3715.8
EPS in Rs23.0121.5414.386.32

About Astrazeneca Pharma India


AstraZeneca India was established in 1979. It is headquartered in Bengaluru, Karnataka. AstraZeneca Pharma India Limited (APIL) is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC, United Kingdom. APIL is, hence, an operating company and is engaged in the manufacturing, sales and marketing activities of the group in India. Its R&D centre in the Bengaluru ‘Avishkar’ campus is a part of its global R&D operations. The company got listed on August 17, 1982.

In 2003, the company launched an Oncology product, Arimidex, for the management of breast cancer. However, India’s National Pharmaceutical Pricing Policy of 2012 brought 348 medicines under price control. 15 SKUs across 8 brands of APIL were covered under that list.

In FY 2014-15, APIL entered into 3 Distribution Services Agreements under which APIL, Dr Reddy’s Laboratories and Sun Pharma will co-promote, market and distribute Saxagliptin, Dapagliflozin and Ticagrelor under different brand names in the Indian market. However, the same year, the company closed the API production unit in Yelahanka, Bangalore.

In FY 2017, APIL aligned its portfolio to AstraZeneca’s global therapeutic strategic focus in core areas of Cardio-Metabolism, Oncology and Respiratory. As a part of this process, certain brands were divested in the areas of Antibiotics, Local Anaesthesia, Maternal Health Care and others.

In October 2019, the company launched Lynparza, which later got the approval to be the first-line treatment of Ovarian Cancer and also for the treatment of metastatic castrate-resistant prostate cancer with HRR mutations. It launched its new product in the Hematology segment, Calquence. In 2022-23, Fasenra, the first Biologic from AstraZeneca to treat Severe Eosinophilic Asthma (SEA) was given to more than 400 Patients.

Business Segments

The company is engaged in the manufacture, distribution and marketing of pharmaceutical products. It also provides clinical trials and marketing support services to an overseas group company. For internal reporting purposes, management has organised the Company into a single reportable segment, i.e. the Healthcare segment. Their focus is on the following:

  1. Cardiovascular – This relates to medical solutions related to the heart and blood vessels.
  2. Renal and Metabolism – This relates to kidneys and the overall alimentary and excretory system.
  3. Oncology – This is related to cancer cure.
  4. Respiratory – This relates to the solutions for the respiratory system.
  5. Rare diseases – This is one of the areas where the most innovative medicines and supporting technologies are required.
  6. Biopharmaceuticals – This involves producing biological organisms that can act as medical solutions.


The company does not have any subsidiaries.

Key Personnel

Sanjeev Panchal, Country President and Managing Director

Mr Panchal is the Country President and MD of AstraZeneca India (Plc). In previous role as CP for AZ Malaysia, he was instrumental in transforming the business to achieve double-digit growth, outpacing the market. He was also a Vice President at PhAMA, i.e. an industry association. He was in the Board of Directors for the British Malaysia Chamber of Commerce, where he actively chaired the Malaysia Cancer Care Coalition.

Corporate Actions

The company has performed the following corporate actions in the recent past:

Stock Split

The company split its stock from a face value of ₹10 to ₹2 with a record date of June 22, 2006.

Mergers and Acquisitions

  • In December 2013, AstraZeneca announced the purchase of Bristol Myers Squibb’s 50% stake in AstraZeneca’s and BMS’s joint diabetes business.
Parent Organisation MNC Associate
Founded 1979
Managing Director Narayan K Seshadri

Peer Comparison

Stocks Market Cap (cr) Market Price (₹) 52 Week Low-High (₹)
Supriya Lifescience Ltd ₹2,787.52


5.20 (1.50%)

346.45 - 354.7
Celestial Biolabs Ltd ₹4.56


0.00 (0.00)

1.75 - 1.8
JFL Life Sciences Ltd ₹52.52


0.00 (0.00)

46 - 47.75
Procter & Gamble Health Ltd ₹8,487.00


7.90 (0.15%)

5062.1 - 5140
Veerhealth Care Ltd ₹45.54


0.00 (0.00)

26 - 26

What's Trending

Astrazeneca Pharma India FAQs

What is the Share price of Astrazeneca Pharma India (ASTRAZEN)?

Astrazeneca Pharma India (ASTRAZEN) share price as of March 2, 2024, on NSE is Rs 5,450.20 (NSE) and Rs 5,439.40 (BSE) on BSE.

Can I buy Astrazeneca Pharma India (ASTRAZEN) shares?

Yes, You can buy Astrazeneca Pharma India (ASTRAZEN) shares by opening a Demat account with Angel One.

How do I buy Astrazeneca Pharma India (ASTRAZEN) from Angel One?

Astrazeneca Pharma India (ASTRAZEN) share can be brought through the following modes:
  1. Direct investment: You can buy Astrazeneca Pharma India (ASTRAZEN) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Astrazeneca Pharma India (ASTRAZEN) shares.

Is AstraZenca Pharma India a Debt free Company?

Yes, AstraZenca Pharma India is a debt free company.

What is the main business of AstraZenca Pharma India?

The main business of AstraZenca Pharma India is to discover, develop, commercialise, and supply medicines for cardiovascular, respiratory, oncology, and renal & metabolic diseases.

Who are the promoters of AstraZenca Pharma India?

The sole promoter of AstraZenca Pharma India is AstraZeneca Pharmaceuticals AB with 75% shareholding.